Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Hepatitis B drug can compromise HIV treatment

Hepatitis B drug can compromise HIV treatment

June 21, 2007

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

In findings published June 21, 2007, online in the journal, the researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine. Entecavir is manufactured by Bristol-Myers Squibb and is marketed under the trade name Baraclude.




The research team was led by Chloe Thio and Howard Hughes Medical Institute investigator Robert Siliciano, both at The Johns Hopkins University School of Medicine. The analyses reported in the paper were performed by lead authors Moira McMahon, Benjamin Jilek, and Timothy Brennan in the Siliciano laboratory.

The group's initial report of the findings in February, 2007, at the Conference on Retroviruses and Opportunistic Infections led the drug's manufacturer, Bristol-Myers Squibb, to change its product labeling to warn of the potential for HIV drug resistance, notify prescribing physicians, and inform the Food and Drug Administration. The United States Department of Health and Human Services now recommends against using entecavir as the first option in treating hepatitis B in co-infected patients who are not already using drugs to suppress HIV. More than 4 million people worldwide are believed to be infected with both viruses.

The scientists emphasized that finding drug resistance in this setting underscores the need to test all antiviral drugs for anti-HIV activity before they are approved for use.

Entecavir is a chemically altered version of a chemical called a nucleoside. The drug blocks viral replication by plugging itself into a polymerase enzyme in the hepatitis B virus that helps produce new viral DNA. However, the hepatitis B polymerase closely resembles the reverse transcriptase enzyme that HIV uses to copy its genome inside an infected cell. Thus, there was a possibility that treating co-infected patients for hepatitis B with entecavir might also have an effect on HIV. But earlier tests by Bristol-Myers Squibb using techniques available at the time did not detect such an effect on HIV, said Siliciano. However, Thio, study co-author Robert Hegarty, and Braden Hale of the Naval Medical Center in San Diego recently identified three co-infected patients in whom entecavir treatment did inhibit HIV replication.

Siliciano and his colleagues analyzed entecavir's effects on HIV using a more sensitive test they had developed to measure inhibition of HIV replication. That test uses a strain of HIV engineered to be capable of only a single round of replication, making the assay more precise. The engineered virus carries the gene for a green fluorescent protein, so that its replication can be readily detected and quantified. The researchers test viral replication inside the same type of immune system T cell that the virus naturally infects.

"This system is an extremely sensitive and reliable way to measure inhibition of HIV replication," said Siliciano. "And when we applied it to test the effects of entecavir, we found the drug did have an effect on HIV. It was quite subtle and relatively easy to miss, but with the right assay it turned out to be a highly reproducible effect."

The researchers' studies revealed that entecavir does inhibit HIV's reverse transcriptase. They also found that one of the patients treated with entecavir developed a specific mutant form of HIV that rendered the virus resistant to lamivudine and emtricitabine.

"This well-known mutation, called M184V, greatly reduces the effectiveness of two of the best anti-HIV drugs," said Siliciano. "So HIV patients not yet on any HIV medications will lose the advantage of treatment with drugs that are part of the most recommended drug regimen for HIV."

The finding offers a broader lesson for drug development, said Siliciano. "I think we need very careful screening of new antiviral agents that have activity against other viruses to make sure that they are not doing the same thing; that is, selecting for HIV resistance. This is particularly a problem for drugs like nucleoside analogs, which might easily affect polymerases from a variety of viruses since all viruses use the nucleoside triphosphates as substrates for synthesizing their genomes," he said.

An especially intriguing finding from the study, added Siliciano, was that entecavir showed a peculiar dosage effect on HIV replication. "Probably the most interesting part of this study was that, while entecavir inhibits HIV infection at a very low concentration-meaning that it has a very high affinity for reverse transcriptase, much better than the drugs that we currently use-it is actually not a very good HIV drug. The inhibition doesn't increase with dosage; it just plateaus. So the overall effect is that entecavir is actually a very potent, but not particularly effective, inhibitor of HIV replication," he said.

Altering the entecavir molecule to eliminate that plateau of effectiveness might well yield a new and effective anti-HIV drug, said Siliciano. Thus, he and his colleagues are further exploring the mechanism of the plateau and how it might be overcome.

Howard Hughes Medical Institute



Related Hepatitis Current Events and Hepatitis News Articles Hepatitis Current Events and Hepatitis News RSS Hepatitis Current Events and Hepatitis News RSS
Toward explaining why hepatitis B hits men harder than women
Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.

Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.

Mount Sinai finds those with more difficult to treat forms of HCV are half as likely to get treated
A new study by Mount Sinai researchers has for the first time found that patients with more difficult to treat forms of hepatitis C are half as likely to initiate treatment for the disease, when compared to patients with hepatitis C that is easier to treat.

Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.

Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.

Liver cells grown from patients' skin cells
Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients' skin cells opening the possibility of treating a wide range of diseases that affect liver function.

Injury and hazards in home health care nursing are a growing concern
Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care.

Medication effective for acute liver failure in early stages of disease
The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.

New aging studies improving vaccine efficacy for the elderly
A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects.
More Hepatitis Current Events and Hepatitis News Articles
Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease

Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease
by Melissa Palmer (Author)

In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death.

In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition, this comprehensive handbook reveals cutting-edge research on the dangers of hepatitis C, one of the world's fasting-growing microbial threats.

Living With Hepatitis C For Dummies

Living With Hepatitis C For Dummies
by Nina L. Paul (Author), Gina Pollichino (Foreword)

A comprehensive, empathetic guide for anyone suffering from this serious liver disease

Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths–about 8,000 to 10,000 people annually–and is the most common reason for liver transplantation. This compassionate guide explains how hepatitis C affects the liver and the body and provides solid advice on today’s treatment options–from drugs (and their side effects) to transplants and alternative therapies–as well as tips on dealing with the emotional and financial burdens the disease brings with it.

Nina L Paul, PhD (New York, NY) earned her doctorate in infectious...

HEPATITIS GIANT MICROBE

HEPATITIS GIANT MICROBE
by Giant Microbes

HAV is spread primarily by unsanitary food and water ? HBV is transmitted in bodily fluids and can cause chronic liver disease ? HCV is perhaps the most dangerous: no vaccine is available

? HDV occurs only in the presence of HBV ? HEV is relatively mild
and non-chronic ? HFV and HGV are newly identified; their connection with liver disease is debated

Understanding Hepatitis C

Understanding Hepatitis C

Part of the award winning public television series Healthy Body/Healthy Mind. Hepatitis C is a blood born disease affecting over 5 million Americans. Dangerously, most people infected aren't even aware they've contracted it. On this program, Infectious Disease Specialists discuss the latest scientific & clinical data including treatment options and their side effects. We visit with real people who for years were unaware they were carrying the virus, found out, sought proper treatment and now live virus free.

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

Home Access Hepatitis C Check 1 ea

Home Access Hepatitis C Check 1 ea
by Home Access

At-Home Telemedicine Test Service for Hepatitis C*.
Confidentia

  Aids & Hepatitis Digest
by Ccm International Ltd


Provides information to Air Force comptroller personell relating to mission accomplishment, to assist them in solving problems and improving efficiency of operation and to communicate new developments and techniques


The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing

The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing
by Misha Ruth Cohen O.M.D. L. Ac. (Author), Robert Gish (Author), Kalia Doner (Author)

A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no idea they are being attacked by something they can't even detect. Now, the two experts on Hepatitis C who teamed up to write the first comprehensive guide to orthodox and alternative treatment options have revised and fully updated the book to include recent findings in the field. Along with programs for self-care, nutritional and fitness plans and a comprehensive Western and Chinese medical...

Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle

Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle
by Balanceuticals

Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Understanding Hepatitis Anatomical Chart Laminated (In Stock)-9992PL1.5

Understanding Hepatitis Anatomical Chart Laminated (In Stock)-9992PL1.5
by Anatomical Chart Company

Defines viral hepatitis and the types of hepatic viruses that cause this disease: Hepatitis A, B, C, D, E, and recently discovered viruses G and TTV (Transfusion Transmitted Virus). Talks about modes of tranmission and illustrated the complications of hepatitis. Illustrates the anatomy of the liver, pancreas and surrounding structures, including veins and arteries. Shows 3 liver biopsies: normal, mild hepatitis and moderate. Lists the signs and symptoms which progress by stages.

Hepatitis C Awareness Ribbon Mouse Pad

Hepatitis C Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Hepatitis C Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Hepatitis C Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Hepatitis C Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

© 2009 BrightSurf.com